Form 4: Zimmer Biomet CEO Ivan Tornos Reports Stock Transactions

Zimmer Biomet's President & CEO, Ivan Tornos, reports the vesting of restricted stock units and subsequent stock transactions to cover tax obligations.

Summary

• Ivan Tornos, President & CEO of Zimmer Biomet Holdings, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On March 6, 2025, 10,268 restricted stock units (RSUs) vested, each representing a contingent right to receive one share of Zimmer Biomet common stock.
• Tornos acquired 10,268 shares of common stock upon the vesting of these RSUs.
• Simultaneously, 5,679 shares were withheld by the company to satisfy tax withholding obligations at a price of $104.86 per share.
• Tornos disposed of 57,432 shares of common stock.
• Following these transactions, Tornos directly owns 51,753 shares of Zimmer Biomet common stock and 10,268 restricted stock units.
• The remaining RSUs will vest on March 6, 2026.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Future Outlook

The remaining RSUs will vest on March 6, 2026.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding the holdings and transactions of key company personnel.

Stakeholder Impact

• The filing provides transparency to shareholders regarding executive stock ownership.
• The transactions have a minor impact on the overall shareholding structure.

Key Dates